A Novel Influenza Virus Hemagglutinin-respiratory Syncytial Virus (RSV) Fusion Protein Subunit Vaccine Against Influenza and RSV

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2013 Aug 2

PMID 23903841

Citations 5

Authors

Tiffany M Turner

Les P Jones

S Mark Tompkins

Ralph A Tripp

Affiliations

Soon will be listed here.

Abstract

Influenza A virus and respiratory syncytial virus (RSV) cause substantial morbidity and mortality afflicting the ends of the age spectrum during the autumn through winter months in the United States. The benefit of vaccination against RSV and influenza using a subunit vaccine to enhance immunity and neutralizing antibody was investigated. Influenza virus hemagglutinin (HA) and RSV fusion (F) protein were tested as vaccine components alone and in combination to explore the adjuvant properties of RSV F protein on HA immunity. Mice vaccinated with HA and F exhibited robust immunity that, when challenged, had reduced viral burden for both influenza and RSV. These studies show an enhancing and cross-protective benefit of F protein for anti-HA immunity.

Citing Articles

Respiratory Syncytial Virus Infection: Treatments and Clinical Management.

Malik S, Ahmad T, Muhammad K, Waheed Y Vaccines (Basel). 2023; 11(2).

PMID: 36851368 PMC: 9962240. DOI: 10.3390/vaccines11020491.

Bacterial and viral infections and related inflammatory responses in chronic obstructive pulmonary disease.

DAnna S, Maniscalco M, Cappello F, Carone M, Motta A, Balbi B Ann Med. 2020; 53(1):135-150.

PMID: 32997525 PMC: 7877965. DOI: 10.1080/07853890.2020.1831050.

Virus genes and host correlates of pathology are markedly reduced during respiratory syncytial and influenza virus co-infection in BALB/c mice.

Ayegbusi O, Ajagbe O, Afowowe T, Aransi A, Olusola B, Awogbindin I Heliyon. 2019; 5(1):e01094.

PMID: 30623128 PMC: 6319304. DOI: 10.1016/j.heliyon.2018.e01094.

Hyperosmolarity impedes the cross-priming competence of dendritic cells in a TRIF-dependent manner.

Popovic Z, Embgenbroich M, Chessa F, Nordstrom V, Bonrouhi M, Hielscher T Sci Rep. 2017; 7(1):311.

PMID: 28331179 PMC: 5428499. DOI: 10.1038/s41598-017-00434-y.

Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies.

Wang S, Liu H, Zhang X, Qian F Protein Cell. 2015; 6(7):480-503.

PMID: 25944045 PMC: 4491048. DOI: 10.1007/s13238-015-0164-2.

References

Chowell G, Bertozzi S, Colchero M, Lopez-Gatell H, Alpuche-Aranda C, Hernandez M . Severe respiratory disease concurrent with the circulation of H1N1 influenza. N Engl J Med. 2009; 361(7):674-9. DOI: 10.1056/NEJMoa0904023. View

Schepens B, Ibanez L, De Baets S, Hultberg A, Bogaert P, De Bleser P . Nanobodies® specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion. J Infect Dis. 2011; 204(11):1692-701. DOI: 10.1093/infdis/jir622. View

Connors M, Giese N, Kulkarni A, Firestone C, Morse 3rd H, Murphy B . Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol. 1994; 68(8):5321-5. PMC: 236482. DOI: 10.1128/JVI.68.8.5321-5325.1994. View

Murphy B, Walsh E . Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol. 1988; 26(8):1595-7. PMC: 266671. DOI: 10.1128/jcm.26.8.1595-1597.1988. View

Kim S, Chang J . Baculovirus-based Vaccine Displaying Respiratory Syncytial Virus Glycoprotein Induces Protective Immunity against RSV Infection without Vaccine-Enhanced Disease. Immune Netw. 2012; 12(1):8-17. PMC: 3329602. DOI: 10.4110/in.2012.12.1.8. View

Haynes L, Jones L, Barskey A, Anderson L, Tripp R . Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P. J Virol. 2003; 77(18):9831-44. PMC: 224581. DOI: 10.1128/jvi.77.18.9831-9844.2003. View

Zhang W, Choi Y, Haynes L, Harcourt J, Anderson L, Jones L . Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice. J Virol. 2009; 84(2):1148-57. PMC: 2798341. DOI: 10.1128/JVI.01755-09. View

Sorrentino M, Powers T . Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group. Pediatr Infect Dis J. 2000; 19(11):1068-71. DOI: 10.1097/00006454-200011000-00007. View

Tamura S, Funato H, Nagamine T, Aizawa C, Kurata T . Effectiveness of cholera toxin B subunit as an adjuvant for nasal influenza vaccination despite pre-existing immunity to CTB. Vaccine. 1989; 7(6):503-5. DOI: 10.1016/0264-410x(89)90273-9. View

10.

Piedra P, Grace S, Jewell A, Spinelli S, Bunting D, Hogerman D . Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr Infect Dis J. 1996; 15(1):23-31. DOI: 10.1097/00006454-199601000-00006. View

11.

Wertz G, Stott E, Young K, Anderson K, Ball L . Expression of the fusion protein of human respiratory syncytial virus from recombinant vaccinia virus vectors and protection of vaccinated mice. J Virol. 1987; 61(2):293-301. PMC: 253949. DOI: 10.1128/JVI.61.2.293-301.1987. View

12.

KILBOURNE E, SCHULMAN J, Schild G, Schloer G, Swanson J, Bucher D . Related studies of a recombinant influenza-virus vaccine. I. Derivation and characterization of virus and vaccine. J Infect Dis. 1971; 124(5):449-62. DOI: 10.1093/infdis/124.5.449. View

13.

Vanderlinden E, Goktas F, Cesur Z, Froeyen M, Reed M, Russell C . Novel inhibitors of influenza virus fusion: structure-activity relationship and interaction with the viral hemagglutinin. J Virol. 2010; 84(9):4277-88. PMC: 2863778. DOI: 10.1128/JVI.02325-09. View

14.

Simoes E, Tan D, Ohlsson A, Sales V, Wang E . Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines. Vaccine. 2001; 20(5-6):954-60. DOI: 10.1016/s0264-410x(01)00388-7. View

15.

Brideau R, Walters R, Stier M, Wathen M . Protection of cotton rats against human respiratory syncytial virus by vaccination with a novel chimeric FG glycoprotein. J Gen Virol. 1989; 70 ( Pt 10):2637-44. DOI: 10.1099/0022-1317-70-10-2637. View

16.

Tristram D, Welliver R, Hogerman D, Hildreth S, Paradiso P . Second-year surveillance of recipients of a respiratory syncytial virus (RSV) F protein subunit vaccine, PFP-1: evaluation of antibody persistence and possible disease enhancement. Vaccine. 1994; 12(6):551-6. DOI: 10.1016/0264-410x(94)90316-6. View

17.

Subbarao K, Joseph T . Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev Immunol. 2007; 7(4):267-78. PMC: 7097526. DOI: 10.1038/nri2054. View

18.

Maria Ropero-Alvarez A, Kurtis H, Danovaro-Holliday M, Ruiz-Matus C, Andrus J . Expansion of seasonal influenza vaccination in the Americas. BMC Public Health. 2009; 9:361. PMC: 2764707. DOI: 10.1186/1471-2458-9-361. View

19.

Crowe Jr J, Collins P, London W, Chanock R, Murphy B . A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine. 1993; 11(14):1395-404. DOI: 10.1016/0264-410x(93)90168-w. View

20.

Miao C, Radu G, Caidi H, Tripp R, Anderson L, Haynes L . Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice. J Gen Virol. 2009; 90(Pt 5):1119-1123. PMC: 2887562. DOI: 10.1099/vir.0.009308-0. View